Related Experiment Video
Updated: Jun 10, 2026
03:55
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
Adjuvant external beam radiation for medullary thyroid carcinoma
Steve R Martinez1, Shannon H Beal, Allen Chen
1Division of Surgical Oncology, Department of Surgery, UC Davis Cancer Center, University of California at Davis, Sacramento, California 95817, USA. steve.martinez@ucdmc.ucdavis.edu
Journal of Surgical Oncology
|July 22, 2010
Summary
External beam radiation therapy (EBRT) did not improve overall survival for medullary thyroid carcinoma patients. While univariate analysis suggested a benefit in node-positive cases, this was not confirmed in multivariate models.
Area of Science:
- Oncology
- Thyroid Cancer Research
- Radiation Oncology
Background:
- Medullary thyroid carcinoma (MTC) rarely utilizes adjuvant radiation therapy.
- External beam radiation therapy (EBRT) is a potential treatment modality for MTC.
Purpose of the Study:
- To investigate the efficacy of EBRT in improving overall survival (OS) for MTC patients.
- To determine if EBRT impacts survival rates based on patient and tumor characteristics.
Main Methods:
- Utilized the Surveillance, Epidemiology, and End Results (SEER) database for MTC patients undergoing total thyroidectomy and lymph node excision (1988-2004).
- Employed Kaplan-Meier for univariate OS comparisons and multivariate Cox proportional hazards models.
- Controlled for variables including gender, age, lymph node status, tumor size, disease extent, and EBRT.
Main Results:
- EBRT did not significantly improve overall survival (OS) in MTC patients after 12 years (P < 0.14).
- Univariate analysis indicated a potential OS benefit with EBRT in node-positive MTC patients (P < 0.05).
- Multivariate analysis revealed that only increasing age and tumor size significantly impacted OS in node-positive patients, negating the EBRT benefit.
Conclusions:
- The observed OS benefit of EBRT in node-positive MTC patients from univariate analysis was not sustained when controlling for key prognostic factors.
- Adjuvant EBRT does not appear to significantly improve overall survival in medullary thyroid carcinoma patients.
- Age and tumor size are critical prognostic factors influencing survival in node-positive MTC patients.
